Quick Answer
ASSEMBLY BIOSCIENCES, INC. reported Total Revenue of $72.30 million for fiscal year 2025.
ASSEMBLY BIOSCIENCES, INC. — Key Financials by Year
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|
| Total Revenue | $72.30M +153.5% |
$28.52M | — | — | — | — |
| Revenue (ASC 606) | $72.30M +153.5% |
$28.52M | — | — | — | — |
| Net Income | -$6.12M +84.8% |
-$40.18M +34.4% |
-$61.23M +34.2% |
-$93.09M +28.3% |
-$129.85M -108.9% |
-$62.15M +36.3% |
| Diluted EPS | -$0.55 +91.8% |
-$6.69 +50.0% |
-$13.38 +42.0% |
-$23.08 -669.3% |
-$3.00 | — |
| Total Assets | $257.59M +116.2% |
$119.17M -12.9% |
$136.82M +34.4% |
$101.79M -46.7% |
$191.06M -32.5% |
$283.25M -16.7% |
| Cash and Equivalents | $58.45M +52.4% |
$38.34M +93.3% |
$19.84M -62.1% |
$52.42M +14.9% |
$45.63M -23.2% |
$59.44M +27.2% |
| Stockholders Equity | $206.75M +519.8% |
$33.36M -18.8% |
$41.10M -50.3% |
$82.66M -51.1% |
$168.93M -29.8% |
$240.58M -11.9% |
| R&D Expense | $64.81M +15.9% |
$55.93M +14.4% |
$48.90M -30.1% |
$69.98M +2.1% |
$68.52M -35.9% |
$106.82M +24.6% |
| Operating Income | -$12.12M +73.3% |
-$45.42M +29.7% |
-$64.65M +31.3% |
-$94.11M +29.1% |
-$132.69M -104.8% |
-$64.78M +36.9% |
| Shares Outstanding | 15.86M +112.6% |
7.46M +36.0% |
5.48M +34.6% |
4.07M -91.5% |
48.12M +41.4% |
34.03M +4.5% |
Most Recent Quarter
| Metric | Quarter Ending | Value | YoY | QoQ |
|---|---|---|---|---|
| Total Revenue | March 31, 2019 | $3.88M | +9.0% | -9.4% |
| Net Income | September 30, 2025 | -$9.20M | +4.3% | +9.8% |
| Diluted EPS | September 30, 2025 | -$0.72 | +52.3% | +45.9% |
| Total Assets | September 30, 2025 | $240.00M | +139.4% | +197.1% |
| Cash and Equivalents | September 30, 2025 | $22.53M | -20.8% | -6.1% |
| Stockholders Equity | September 30, 2025 | $182.69M | +602.6% | +909.4% |
| R&D Expense | September 30, 2025 | $16.59M | +22.7% | +2.9% |
| Operating Income | September 30, 2025 | -$10.88M | +0.7% | +1.9% |
| Shares Outstanding | September 30, 2025 | 15.82M | +148.9% | +106.2% |
- ASSEMBLY BIOSCIENCES, INC. reported Total Revenue of $72.30 million for fiscal year 2025.
- ASSEMBLY BIOSCIENCES, INC. showed an increase of +153.5% in Total Revenue compared to the prior fiscal year.
- ASSEMBLY BIOSCIENCES, INC. reported Revenue (ASC 606) of $72.30 million for fiscal year 2025.
- ASSEMBLY BIOSCIENCES, INC. showed an increase of +153.5% in Revenue (ASC 606) compared to the prior fiscal year.
- ASSEMBLY BIOSCIENCES, INC. reported Net Income of -$6.12 million for fiscal year 2025.
- ASSEMBLY BIOSCIENCES, INC. showed an increase of +84.8% in Net Income compared to the prior fiscal year.
- ASSEMBLY BIOSCIENCES, INC. reported Diluted EPS of $0.55 per share (loss) for fiscal year 2025.
- ASSEMBLY BIOSCIENCES, INC. showed an increase of +91.8% in Diluted EPS compared to the prior fiscal year.
- ASSEMBLY BIOSCIENCES, INC. reported Total Assets of $257.59 million for fiscal year 2025.
- ASSEMBLY BIOSCIENCES, INC. showed an increase of +116.2% in Total Assets compared to the prior fiscal year.
- ASSEMBLY BIOSCIENCES, INC. reported Cash and Equivalents of $58.45 million for fiscal year 2025.
- ASSEMBLY BIOSCIENCES, INC. showed an increase of +52.4% in Cash and Equivalents compared to the prior fiscal year.
- ASSEMBLY BIOSCIENCES, INC. reported Stockholders Equity of $206.75 million for fiscal year 2025.
- ASSEMBLY BIOSCIENCES, INC. showed an increase of +519.8% in Stockholders Equity compared to the prior fiscal year.
- ASSEMBLY BIOSCIENCES, INC. reported R&D Expense of $64.81 million for fiscal year 2025.
- ASSEMBLY BIOSCIENCES, INC. showed an increase of +15.9% in R&D Expense compared to the prior fiscal year.
- ASSEMBLY BIOSCIENCES, INC. reported Operating Income of -$12.12 million for fiscal year 2025.
- ASSEMBLY BIOSCIENCES, INC. showed an increase of +73.3% in Operating Income compared to the prior fiscal year.
- ASSEMBLY BIOSCIENCES, INC. reported Shares Outstanding of 15.86 million shares for fiscal year 2025.
- ASSEMBLY BIOSCIENCES, INC. showed an increase of +112.6% in Shares Outstanding compared to the prior fiscal year.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: